LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics

Lymphocyte activation gene 3 (LAG-3) serves as an immune checkpoint that attenuates T-cell activation. Antibodies targeting LAG-3, such as relatlimab, have the potential to enhance the activity of other checkpoint inhibitors when given in combination. This study assessed RNA expression levels of 397 genes in 514 diverse cancers, revealing that 22.6% of tumors had high LAG-3 transcript expression, with melanoma, neuroendocrine, and uterine cancers showing the highest proportions. High LAG-3 expression was associated with elevated expression of other checkpoints including PD-1, PD-L1, and CTLA-4, as well as high TMB. This study suggest that analysis of individual immune profiles could guide personalized immunotherapy approaches.

View the Graphical Summary